Ligand validation:8EL5

AX9: DiCys-(15,16)-Dihydrobiliverdin

AX9 is a Ligand Of Interest in 8EL5 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8EL5_AX9_B_201	85%	25%	0.078	0.942	1.67	1.41	9	7	0	0	100%	1
8EL5_AX9_H_201	85%	29%	0.078	0.941	1.72	1.15	8	5	0	0	100%	1
8EL5_AX9_D_201	84%	27%	0.078	0.939	1.6	1.36	10	6	0	0	100%	1
8EL5_AX9_F_201	75%	22%	0.088	0.921	1.77	1.47	12	6	0	0	100%	1
7SUT_AX9_H_201	97%	32%	0.057	0.971	1.6	1.13	8	2	0	0	100%	1
8EL3_AX9_B_201	88%	26%	0.083	0.957	1.62	1.4	9	6	0	0	100%	1
7SSF_AX9_B_201	87%	27%	0.086	0.959	1.52	1.44	8	9	0	0	100%	0.54
8EL6_AX9_B_201	85%	24%	0.084	0.95	1.59	1.52	9	7	2	0	100%	1
8EL4_AX9_D_201	75%	26%	0.091	0.924	1.71	1.31	11	7	0	0	100%	1
7T89_AX9_B_201	94%	36%	0.075	0.975	1.49	1.04	10	2	0	0	100%	0.64
7T7U_AX9_D_303	86%	27%	0.099	0.969	1.56	1.41	7	6	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.